| pubmed-article:9855321 | pubmed:abstractText | To assess the potential for a drug-drug interaction between valspodar, a P-glycoprotein (mdrl) modulator used as a chemotherapy adjunct, and dexamethasone, widely included in oncology antiemetic regimens. | lld:pubmed |
